Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | SCN4A | P35499 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 1.00 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 1.00 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.58 |
| ▸ | TNIK | Q9UKE5 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.44 |
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eleclazine SCHEMBL29377130 | 1.00 | KCNH2 (1.00) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| Eleclazine SCHEMBL16989336 | 0.99 | KCNH2 (0.98) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| Eleclazine SCHEMBL16989318 | 0.95 | KCNH2 (0.91) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| Eleclazine SCHEMBL16989319 | 0.94 | KCNH2 (0.88) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| Eleclazine SCHEMBL16989317 | 0.94 | KCNH2 (0.88) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| SCHEMBL17014542 | 0.92 | SCN1A (0.86) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| SCHEMBL14480581 | 0.92 | SCN1A (0.85) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| SCHEMBL15120132 | 0.92 | KCNH2 (0.85) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| Eleclazine SCHEMBL16989316 | 0.91 | KCNH2 (0.84) | KCNH2SCN1ASCN4ASCN5ASCN9A | |
| Eleclazine SCHEMBL19923836 | 0.91 | KCNH2 (0.84) | KCNH2SCN1ASCN4ASCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076961-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2026-03-19 | — | — | US | claimed |
| EP-3579840-B1 | TREATMENT OF CANCER AND INHIBITION OF METASTASIS | CELEX ONCOLOGY INNOVATIONS LTD (GB) | 2023-06-07 | — | — | EP | claimed |
| US-20220347172-A1 | COMBINATION TREATMENTS | Celex Oncology Innovations Limited (GB) | 2022-11-03 | — | — | US | claimed |
| EP-4048274-A1 | COMBINATION TREATMENTS FOR CANCER | Celex Oncology Innovations Limited (GB) | 2022-08-31 | — | — | EP | claimed |
| CN-114828853-A | Combination therapy for cancer | 赛立斯肿瘤学创新有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20220125800-A1 | TREATMENT OF CANCER AND INHIBITION OF METASTASIS | Celex Oncology Innovations Limited (GB) | 2022-04-28 | — | — | US | claimed |
| WO-2021078987-A1 | COMBINATION TREATMENTS FOR CANCER | Celex Oncology Innovations Limited (GB) | 2021-04-29 | — | — | WO | claimed |
| US-20200069697-A1 | TREATMENT OF CANCER AND INHIBITION OF METASTASIS | CELEX GMBH (CH) | 2020-03-05 | — | — | US | claimed |
| WO-2018146313-A1 | TREATMENT OF CANCER AND INHIBITION OF METASTASIS | CELEX GMBH (CH) | 2018-08-16 | — | — | WO | claimed |
| US-20170007617-A1 | INTRAVENOUS FORMULATIONS OF A LATE SODIUM CURRENT INHIBITOR | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | claimed |
| US-20150225383-A1 | SOLID FORMS OF AN ION CHANNEL MODULATOR | GILEAD SCIENCES, INC. | 2015-08-13 | — | — | US | claimed |
| US-20150045305-A1 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | claimed |
| EP-2806865-A1 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS | Gilead Sciences, Inc. (US) | 2014-12-03 | — | — | EP | claimed |
| EP-2726466-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| US-8697863-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-04-15 | — | — | US | claimed |
| US-8586732-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | claimed |
| WO-2013112932-A1 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | WO | claimed |
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | US | claimed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | claimed |
| WO-2013006485-A1 | FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | KCNH2 5/4885SCN1A 64/4885SCN4A 39/4885 |
| US-20220125800-A1 | TREATMENT OF CANCER AND INHIBITION OF METASTASIS | CACNB2, CACNB1, CACNA1G | KCNH2 75/4885SCN1A 39/4885SCN4A 68/4885 |
| US-20170007617-A1 | INTRAVENOUS FORMULATIONS OF A LATE SODIUM CURRENT INHIBITOR | KCNN1, KCNN2, KCNN3 | KCNH2 13/4885SCN1A 29/4885SCN4A 5/4885 |
| US-20150045305-A1 | COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS | KCNH1, KCNN3, KCNB2 | KCNH2 8/4885SCN1A 48/4885SCN4A 22/4885 |
| US-20200069697-A1 | TREATMENT OF CANCER AND INHIBITION OF METASTASIS | CACNB2, CACNB1, CACNA1G | KCNH2 75/4885SCN1A 39/4885SCN4A 68/4885 |
| US-20260076961-A1 | COMBINATION TREATMENTS | SCNN1B, SCN2B, SCNN1A | KCNH2 34/4885SCN1A 5/4885SCN4A 16/4885 |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | KCNH2 5/4885SCN1A 64/4885SCN4A 39/4885 |
| US-20150225383-A1 | SOLID FORMS OF AN ION CHANNEL MODULATOR | KCNN1, SCN4A, KCNN2 | KCNH2 13/4885SCN1A 19/4885SCN4A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.